Art. -Nr.: HY-13677

6-Mercaptopurine

(Synonyms: Mercaptopurine; 6-MP)

18 Cited Publications

Kundenbewertung

Based on 18 publication(s) in Google Scholar

6-Mercaptopurine is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive drug.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.93%
CAS. Nr.: 50-44-2
Formel: C₅H₄N₄S
Molecular Weight:152.18

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

6-Mercaptopurine Chemical Structure

CAS. Nr.: 50-44-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (18)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

6-Mercaptopurine is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive drug.

IC₅₀ & Target

endogenous purines^[1]

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	47 μM Compound: 6-mercaptopurine	Cytotoxicity against human A549 cells at lag phase of growth after 48 hrs by MTT assay Cytotoxicity against human A549 cells at lag phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
A549	IC₅₀	49.3 μM Compound: 6-mercaptopurine	Cytotoxicity against human A549 cells at exponential phase of growth after 48 hrs by MTT assay Cytotoxicity against human A549 cells at exponential phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
A549	IC₅₀	47 μM Compound: C2	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 22705001]
A549	IC₅₀	47 μM Compound: C2	Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
A549	IC₅₀	49.4 μM Compound: C2	Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
ASPC1	IC₅₀	2.45 μM Compound: 6-MP	Cytotoxicity against human Aspc-1 cells by crystal violet staining Cytotoxicity against human Aspc-1 cells by crystal violet staining	[PMID: 20930123]
B16	IC₅₀	0.8 μg/mL Compound: 6-MP	Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay	[PMID: 7807120]
C6	IC₅₀	30.2 μg/mL Compound: 6-MP	Cytotoxicity against rat C6 cells assessed as cell viability after 96 hrs by MTT assay Cytotoxicity against rat C6 cells assessed as cell viability after 96 hrs by MTT assay	[PMID: 11087619]
CCRF-CEM	IC₅₀	1 μM Compound: 6MP	Antiproliferative activity against human CCRF-CEM cells by MTT assay Antiproliferative activity against human CCRF-CEM cells by MTT assay	[PMID: 17254669]
CCRF-CEM	CC₅₀	1 μM Compound: 6MP	Antiproliferative activity against human CCRF-CEM cells after 96 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells after 96 hrs by MTT assay	[PMID: 21741130]
CCRF-SB	IC₅₀	1 μM Compound: 6MP	Antiproliferative activity against human CCRF-SB cells by MTT assay Antiproliferative activity against human CCRF-SB cells by MTT assay	[PMID: 17254669]
CCRF-SB	CC₅₀	1.1 μM Compound: 6MP	Antiproliferative activity against human CCRF-SB cells after 96 hrs by MTT assay Antiproliferative activity against human CCRF-SB cells after 96 hrs by MTT assay	[PMID: 21741130]
CHO	ED₅₀	50 μM Compound: 6MP	Cytotoxicity against CHO cells Cytotoxicity against CHO cells	[PMID: 23411915]
COLO357	IC₅₀	6.12 μM Compound: 6-MP	Cytotoxicity against human Colo-357 cells by crystal violet staining Cytotoxicity against human Colo-357 cells by crystal violet staining	[PMID: 20930123]
CRL-7065 cell line	IC₅₀	>100 μM Compound: 6MP	Antiproliferative activity against human CRL7065 cells by MTT assay Antiproliferative activity against human CRL7065 cells by MTT assay	[PMID: 17254669]
DAN-G	IC₅₀	4.06 μM Compound: 6-MP	Cytotoxicity against human DAN-G cells by crystal violet staining Cytotoxicity against human DAN-G cells by crystal violet staining	[PMID: 20930123]
Daudi	IC₅₀	>200 μM Compound: 6-MP	Antiproliferative activity against human Daudi cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay Antiproliferative activity against human Daudi cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay	[PMID: 18467007]
DU-145	IC₅₀	2 μM Compound: 6MP	Antiproliferative activity against human DU145 cells by MTT assay Antiproliferative activity against human DU145 cells by MTT assay	[PMID: 17254669]
DU-145	CC₅₀	2 μM Compound: 6MP	Antiproliferative activity against human DU145 cells after 96 hrs by MTT assay Antiproliferative activity against human DU145 cells after 96 hrs by MTT assay	[PMID: 21741130]
HEK293	IC₅₀	0.007 μM Compound: 6-MP	Antiproliferative activity against HEK293 cells assessed as reduction of cell growth after 72 hrs by MTT method Antiproliferative activity against HEK293 cells assessed as reduction of cell growth after 72 hrs by MTT method	[PMID: 10757708]
HEK293	IC₅₀	0.007 μM Compound: 6-MP	Antiproliferative activity against HEK293 cells after 3 days by MTT conversion assay Antiproliferative activity against HEK293 cells after 3 days by MTT conversion assay	[PMID: 16643040]
HEK293	IC₅₀	0.007 μM Compound: 6-MP	Antiproliferative activity against HEK293 cells after 72 hrs by MTT conversion assay Antiproliferative activity against HEK293 cells after 72 hrs by MTT conversion assay	[PMID: 16989528]
HEK293	IC₅₀	0.007 μM Compound: 6-MP	Antiproliferative activity against human HEK293 cells after 72 hrs by MTT conversion assay Antiproliferative activity against human HEK293 cells after 72 hrs by MTT conversion assay	[PMID: 18442289]
HEK293	IC₅₀	7.1 x 10^-7 mg/mL Compound: 6-mercaptopurine	Cytotoxicity against HEK293 cells by rapid colorimetric assay Cytotoxicity against HEK293 cells by rapid colorimetric assay	[PMID: 19133758]
HeLa	IC₅₀	>200 μM Compound: 6-MP	Antiproliferative activity against human HeLa cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay Antiproliferative activity against human HeLa cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay	[PMID: 18467007]
HeLa	IC₅₀	2.9 μM Compound: 6-mercaptopurine	Cytotoxicity against human HeLa cells at lag phase of growth after 48 hrs by MTT assay Cytotoxicity against human HeLa cells at lag phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
HeLa	IC₅₀	4.1 μM Compound: 6-mercaptopurine	Cytotoxicity against human HeLa cells at exponential phase of growth after 48 hrs by MTT assay Cytotoxicity against human HeLa cells at exponential phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
HeLa	IC₅₀	2.9 μM Compound: C2	Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 22705001]
HeLa	IC₅₀	2.9 μM Compound: C2	Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
HeLa	IC₅₀	4.1 μM Compound: C2	Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
HeLa	ED₅₀	0.1 μg/mL Compound: 6-mercaptopurine	Cytostatic activity against human HeLa cells after 72 hrs by FCR-based colorimetric method Cytostatic activity against human HeLa cells after 72 hrs by FCR-based colorimetric method	[PMID: 448680]
HeLa	ED₅₀	0.1 μg/mL Compound: 6-mercaptopurine	In vitro cytostatic activity against human HeLa cells assessed as cell growth after 72 hrs by colorimetric method In vitro cytostatic activity against human HeLa cells assessed as cell growth after 72 hrs by colorimetric method	[PMID: 458800]
HeLa	ED₅₀	0.1 μg/mL Compound: 6-Mercaptopurine	Cytostatic activity against human HeLa cells assessed as growth inhibition after 72 hrs by colorimetric method Cytostatic activity against human HeLa cells assessed as growth inhibition after 72 hrs by colorimetric method	[PMID: 671455]
HEp-2	IC₅₀	317.8 μM Compound: 6-mercaptopurine	Cytotoxicity against human Hep2 cells at exponential phase of growth after 48 hrs by MTT assay Cytotoxicity against human Hep2 cells at exponential phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
HEp-2	IC₅₀	431 μM Compound: 6-mercaptopurine	Cytotoxicity against human Hep2 cells at lag phase of growth after 48 hrs by MTT assay Cytotoxicity against human Hep2 cells at lag phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
HepG2	IC₅₀	8 μM Compound: 6MP	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 17254669]
HepG2	CC₅₀	8 μM Compound: 6MP	Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay	[PMID: 21741130]
HT-29	IC₅₀	>200 μM Compound: 6-MP	Antiproliferative activity against multidrug-resistant human HT-29 cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay Antiproliferative activity against multidrug-resistant human HT-29 cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay	[PMID: 18467007]
HT-29	IC₅₀	0.87 μg/mL Compound: 6-MP	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 7807120]
IGR-1	IC₅₀	1.1 μg/mL Compound: 6-MP	Antiproliferative activity against human IGR-1 cells after 72 hrs by MTT assay Antiproliferative activity against human IGR-1 cells after 72 hrs by MTT assay	[PMID: 9358643]
IGR-1	IC₅₀	12.3 μg/mL Compound: 6-MP	Antiproliferative activity against human IGR-1 cells after 48 hrs by MTT assay Antiproliferative activity against human IGR-1 cells after 48 hrs by MTT assay	[PMID: 9358643]
IGR-1	IC₅₀	51.7 μg/mL Compound: 6-MP	Cytotoxicity against human IGR-1 cells after 24 hrs by MTT assay Cytotoxicity against human IGR-1 cells after 24 hrs by MTT assay	[PMID: 9358643]
J774	IC₅₀	0.003 μM Compound: 6-MP	Antiproliferative activity against mouse J774 cells assessed as reduction of cell growth after 72 hrs by MTT method Antiproliferative activity against mouse J774 cells assessed as reduction of cell growth after 72 hrs by MTT method	[PMID: 10757708]
J774	IC₅₀	0.5 μg/mL Compound: 6-MP	Antiproliferative activity against mouse J774 cells after 72 hrs by MTT assay Antiproliferative activity against mouse J774 cells after 72 hrs by MTT assay	[PMID: 9358643]
J774	IC₅₀	3.6 μg/mL Compound: 6-MP	Antiproliferative activity against mouse J774 cells after 48 hrs by MTT assay Antiproliferative activity against mouse J774 cells after 48 hrs by MTT assay	[PMID: 9358643]
J774	IC₅₀	61 μg/mL Compound: 6-MP	Cytotoxicity against mouse J774 cells after 24 hrs by MTT assay Cytotoxicity against mouse J774 cells after 24 hrs by MTT assay	[PMID: 9358643]
J774.A1	IC₅₀	0.003 μM Compound: 6-MP	Antiproliferative activity against mouse J774.A1 cells after 3 days by MTT conversion assay Antiproliferative activity against mouse J774.A1 cells after 3 days by MTT conversion assay	[PMID: 16643040]
J774.A1	IC₅₀	0.003 μM Compound: 6-MP	Antiproliferative activity against mouse J774A1 cells after 72 hrs by MTT conversion assay Antiproliferative activity against mouse J774A1 cells after 72 hrs by MTT conversion assay	[PMID: 16989528]
J774.A1	IC₅₀	0.003 μM Compound: 6-MP	Antiproliferative activity against mouse J774.A1 cells after 72 hrs by MTT conversion assay Antiproliferative activity against mouse J774.A1 cells after 72 hrs by MTT conversion assay	[PMID: 18442289]
J774.A1	IC₅₀	5.1 ng/mL Compound: 6-mercaptopurine	Cytotoxicity against mouse J774A1 cells by rapid colorimetric assay Cytotoxicity against mouse J774A1 cells by rapid colorimetric assay	[PMID: 19133758]
J774.A1	IC₅₀	5.1 x 10^-6 mg/mL Compound: 6-mercaptopurine	Cytotoxicity against mouse J774A1 cells by rapid colorimetric assay Cytotoxicity against mouse J774A1 cells by rapid colorimetric assay	[PMID: 19133758]
Jurkat	IC₅₀	>200 μM Compound: 6-MP	Antiproliferative activity against human Jurkat cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay Antiproliferative activity against human Jurkat cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay	[PMID: 18467007]
K562	IC₅₀	0.4 μg/mL Compound: 6-mercaptopurine	Cytotoxicity against chronic myelogenous leukemia cell line K-562 was determined by measuring [3H]thymidine incorporation after 48 h Cytotoxicity against chronic myelogenous leukemia cell line K-562 was determined by measuring [3H]thymidine incorporation after 48 h	[PMID: 11844673]
K562	IC₅₀	8.5 μg/mL Compound: 6-mercaptopurine	Cytotoxicity against chronic myelogenous leukemia cell line K-562 was determined by measuring [3H]thymidine incorporation after 5 h Cytotoxicity against chronic myelogenous leukemia cell line K-562 was determined by measuring [3H]thymidine incorporation after 5 h	[PMID: 11844673]
K562	IC₅₀	>10 μg/mL Compound: 6-MP	Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 5h, using [3H]thymidine incorporation assay Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 5h, using [3H]thymidine incorporation assay	[PMID: 12617912]
K562	IC₅₀	0.6 μg/mL Compound: 6-MP	Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 48h, using [3H]thymidine incorporation assay Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 48h, using [3H]thymidine incorporation assay	[PMID: 12617912]
KB	ED₅₀	0.1 μg/mL Compound: 6-Mercaptopurine	Cytostatic activity against human KB cells assessed as growth inhibition after 72 hrs by colorimetric method Cytostatic activity against human KB cells assessed as growth inhibition after 72 hrs by colorimetric method	[PMID: 671455]
KB	IC₅₀	0.55 μg/mL Compound: 6-MP	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 7807120]
KB	ED₅₀	0.54 μg/mL Compound: mercaptopurine	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 8277314]
L1210	IC₅₀	0.02 μM Compound: 6-MP	Inhibitory concentration on parentral (sensitive) L1210 leukemia cells. Inhibitory concentration on parentral (sensitive) L1210 leukemia cells.	[PMID: 1906107]
L1210	IC₅₀	0.024 μM Compound: 6-MP	Inhibitory concentration on multidrug-resistant L1210 leukemia cells. Inhibitory concentration on multidrug-resistant L1210 leukemia cells.	[PMID: 1906107]
MCF7	IC₅₀	3 μM Compound: 6MP	Antiproliferative activity against human MCF7 cells by MTT assay Antiproliferative activity against human MCF7 cells by MTT assay	[PMID: 17254669]
MCF7	IC₅₀	1.4 μM Compound: 6-mercaptopurine	Cytotoxicity against human MCF7 cells at lag phase of growth after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells at lag phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
MCF7	IC₅₀	5.8 μM Compound: 6-mercaptopurine	Cytotoxicity against human sMCF7 cells at exponential phase of growth after 48 hrs by MTT assay Cytotoxicity against human sMCF7 cells at exponential phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
MCF7	CC₅₀	3.2 μM Compound: 6MP	Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 21741130]
MCF7	IC₅₀	1.4 μM Compound: C2	Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 22705001]
MCF7	IC₅₀	2.79 μM Compound: 6MP	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 23411915]
MCF7	IC₅₀	1.4 μM Compound: C2	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
MCF7	IC₅₀	5.8 μM Compound: C2	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
MOLT-4	IC₅₀	50.5 μM Compound: 6-MP	Antiproliferative activity against human MOLT4 cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay Antiproliferative activity against human MOLT4 cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay	[PMID: 18467007]
MT4	IC₅₀	0.1 μM Compound: 6MP	Antiproliferative activity against human MT4 cells by MTT assay Antiproliferative activity against human MT4 cells by MTT assay	[PMID: 17254669]
MT4	CC₅₀	0.1 μM Compound: 6MP	Cytotoxicity against human MT4 cells infected with HTLV-1 after 96 hrs by MTT assay Cytotoxicity against human MT4 cells infected with HTLV-1 after 96 hrs by MTT assay	[PMID: 21741130]
P388	IC₅₀	0.26 μg/mL Compound: 6-MP	Cytotoxicity against mouse doxorubicin resistant P388 cells after 72 hrs by MTT assay Cytotoxicity against mouse doxorubicin resistant P388 cells after 72 hrs by MTT assay	[PMID: 7807120]
P388	IC₅₀	0.7 μg/mL Compound: 6-MP	Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay	[PMID: 7807120]
P388	ED₅₀	0.25 μg/mL Compound: mercaptopurine	Cytotoxicity against mouse doxorubicin-resistant P388 cells Cytotoxicity against mouse doxorubicin-resistant P388 cells	[PMID: 8277314]
P388	ED₅₀	0.7 μg/mL Compound: mercaptopurine	Cytotoxicity against mouse P388 cells Cytotoxicity against mouse P388 cells	[PMID: 8277314]
P388	IC₅₀	0.3 μg/mL Compound: 6-MP	Antiproliferative activity against mouse P388 cells after 72 hrs by MTT assay Antiproliferative activity against mouse P388 cells after 72 hrs by MTT assay	[PMID: 9358643]
P388	IC₅₀	2.1 μg/mL Compound: 6-MP	Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay	[PMID: 9358643]
P388	IC₅₀	37 μg/mL Compound: 6-MP	Cytotoxicity against mouse P388 cells after 24 hrs by MTT assay Cytotoxicity against mouse P388 cells after 24 hrs by MTT assay	[PMID: 9358643]
PANC-1	IC₅₀	6.39 μM Compound: 6-MP	Cytotoxicity against human PANC1 cells by crystal violet staining Cytotoxicity against human PANC1 cells by crystal violet staining	[PMID: 20930123]
PaTu 8988t	IC₅₀	4.09 μM Compound: 6-MP	Cytotoxicity against human Patu-T cells by crystal violet staining Cytotoxicity against human Patu-T cells by crystal violet staining	[PMID: 20930123]
PBMC	IC₅₀	149.5 nM Compound: 6-MP	Inhibition of T cell mitogen-induced blastogenesis in human PBMC after 4 days Inhibition of T cell mitogen-induced blastogenesis in human PBMC after 4 days	[PMID: 18467007]
REH	IC₅₀	2.94 μM Compound: 6TP	Cytotoxicity against human REH cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay Cytotoxicity against human REH cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay	[PMID: 30774864]
S49	EC₅₀	8 μM Compound: 6-MP	Cytotoxicity against wild type mouse S49 cells assessed as growth inhibition after 72 hrs by trypan blue exclusion assay Cytotoxicity against wild type mouse S49 cells assessed as growth inhibition after 72 hrs by trypan blue exclusion assay	[PMID: 221658]
S49	EC₅₀	>1000 μM Compound: 6-MP	Cytotoxicity against HGPRTase-deficient mouse S49 cells assessed as growth inhibition after 72 hrs by trypan blue exclusion assay Cytotoxicity against HGPRTase-deficient mouse S49 cells assessed as growth inhibition after 72 hrs by trypan blue exclusion assay	[PMID: 221658]
SK-MEL-28	IC₅₀	15 μM Compound: 6MP	Antiproliferative activity against human SK-MEL-28 cells by MTT assay Antiproliferative activity against human SK-MEL-28 cells by MTT assay	[PMID: 17254669]
SK-MEL-28	CC₅₀	15 μM Compound: 6MP	Antiproliferative activity against human SK-MEL-28 cells after 96 hrs by MTT assay Antiproliferative activity against human SK-MEL-28 cells after 96 hrs by MTT assay	[PMID: 21741130]
SK-MES-1	IC₅₀	58 μM Compound: 6MP	Antiproliferative activity against human SKMES1 cells by MTT assay Antiproliferative activity against human SKMES1 cells by MTT assay	[PMID: 17254669]
SK-MES-1	CC₅₀	58 μM Compound: 6MP	Antiproliferative activity against human SKMES1 cells after 96 hrs by MTT assay Antiproliferative activity against human SKMES1 cells after 96 hrs by MTT assay	[PMID: 21741130]
U-937	IC₅₀	>200 μM Compound: 6-MP	Antiproliferative activity against human U937 cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay Antiproliferative activity against human U937 cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay	[PMID: 18467007]
Vero	IC₅₀	118.6 μM Compound: 6-mercaptopurine	Cytotoxicity against african green monkey Vero cells at exponential phase of growth after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells at exponential phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
Vero	IC₅₀	67.5 μM Compound: 6-mercaptopurine	Cytotoxicity against african green monkey Vero cells at lag phase of growth after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells at lag phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
Vero	IC₅₀	67.6 μM Compound: C2	Cytotoxicity against african green monkey Vero cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 22705001]
Vero	IC₅₀	>117 μM Compound: C2	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
Vero	IC₅₀	67.6 μM Compound: C2	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
WEHI-164	IC₅₀	0.017 μM Compound: 6-MP	Antiproliferative activity against mouse WEHI164 cells assessed as reduction of cell growth after 72 hrs by MTT method Antiproliferative activity against mouse WEHI164 cells assessed as reduction of cell growth after 72 hrs by MTT method	[PMID: 10757708]
WEHI-164	IC₅₀	1.3 μg/mL Compound: 6-MP	Cytotoxicity against mouse WEHI164 cells assessed as cell viability after 96 hrs by MTT assay Cytotoxicity against mouse WEHI164 cells assessed as cell viability after 96 hrs by MTT assay	[PMID: 11087619]
WEHI-164	IC₅₀	1.3 μg/mL Compound: 6-MP	Antiproliferative activity against mouse WEHI164 cells assessed as cell viability after 96 hrs by MTT assay Antiproliferative activity against mouse WEHI164 cells assessed as cell viability after 96 hrs by MTT assay	[PMID: 11430005]
WEHI-164	IC₅₀	0.015 μM Compound: 6-MP	Antiproliferative activity against mouse WEHI164 cells after 3 days by MTT conversion assay Antiproliferative activity against mouse WEHI164 cells after 3 days by MTT conversion assay	[PMID: 16643040]
WEHI-164	IC₅₀	0.015 μM Compound: 6-MP	Antiproliferative activity against mouse WEHI164 cells after 72 hrs by MTT conversion assay Antiproliferative activity against mouse WEHI164 cells after 72 hrs by MTT conversion assay	[PMID: 16989528]
WEHI-164	IC₅₀	0.015 μM Compound: 6-MP	Antiproliferative activity against mouse WEHI164 cells after 72 hrs by MTT conversion assay Antiproliferative activity against mouse WEHI164 cells after 72 hrs by MTT conversion assay	[PMID: 18442289]
WEHI-164	IC₅₀	2.5 ng/mL Compound: 6-mercaptopurine	Cytotoxicity against mouse WEHI164 cells by rapid colorimetric assay Cytotoxicity against mouse WEHI164 cells by rapid colorimetric assay	[PMID: 19133758]
WEHI-164	IC₅₀	2.5 x 10^-6 mg/mL Compound: 6-mercaptopurine	Cytotoxicity against mouse WEHI164 cells by rapid colorimetric assay Cytotoxicity against mouse WEHI164 cells by rapid colorimetric assay	[PMID: 19133758]
WEHI-164	IC₅₀	2.7 μg/mL Compound: 6-MP	Antiproliferative activity against mouse WEHI164 cells after 72 hrs by MTT assay Antiproliferative activity against mouse WEHI164 cells after 72 hrs by MTT assay	[PMID: 9358643]
WEHI-164	IC₅₀	42 μg/mL Compound: 6-MP	Antiproliferative activity against mouse WEHI164 cells after 48 hrs by MTT assay Antiproliferative activity against mouse WEHI164 cells after 48 hrs by MTT assay	[PMID: 9358643]
WEHI-164	IC₅₀	83 μg/mL Compound: 6-MP	Cytotoxicity against mouse WEHI164 cells after 24 hrs by MTT assay Cytotoxicity against mouse WEHI164 cells after 24 hrs by MTT assay	[PMID: 9358643]
WIL2-NS	IC₅₀	3 μM Compound: 6MP	Antiproliferative activity against human WIL-2NS cells by MTT assay Antiproliferative activity against human WIL-2NS cells by MTT assay	[PMID: 17254669]
WIL2-NS	CC₅₀	3 μM Compound: 6MP	Antiproliferative activity against human WIL2-NS cells after 96 hrs by MTT assay Antiproliferative activity against human WIL2-NS cells after 96 hrs by MTT assay	[PMID: 21741130]

In Vitro

6-Mercaptopurine hydrate (6-MP) induces NR4A3 transcriptional activity 1.6- to 11-fold (P<0.01) in a dose-responsive manner. It is found that 6-Mercaptopurine hydrate leads to a dose-dependent increase in NR4A3 protein levels. 6-MP treatment increases cell surface GLUT4 in both basal cells 1.8- to 3.6-fold (P<0.01) and insulin-stimulated cells 2.9- to 4.4-fold (P<0.01) over that in controls. It is also found that 6-Mercaptopurine hydrate increases phospho-AS160 significantly in a dose-responsive manner under both basal and insulin-stimulated conditions^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

In the fetal telencephalons of the 6-Mercaptopurine hydrate (6-MP)-treated group, the S phase cell population increases at 36 and 48 h and returns to the control level at 72 h after treatment. The G2/M phase cell population begins to increase at 24 h, peaks at 36 h, decreases at 48 h, and finally returnes to the control level at 72 h. On the other hand, the sub-G1 phase cell population (apoptotic cells) begins to increase at 36 h, peaks at 48 h, and then decreases at 72 h^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 50-44-2
Appearance Solid
Molecular Weight 152.18
Formel C₅H₄N₄S
Color Light yellow to yellow
SMILES

S=C1NC=NC2=C1NC=N2
Synonyms

Mercaptopurine; 6-MP
Structure Classification
- Others
Initial Source
- Endogenous metabolite
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (18)

All WBIn Vivo Efficacy StudyCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Nat Commun

Identification of purine biosynthesis as an NADH-sensing pathway to mediate energy stress. [Abstract]

2022 Nov 17;13(1):7031. PMID: 36396642

6-Mercaptopurine purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Nov 17;13(1):7031. [Abstract]

6-Mercaptopurine (6-MP; 300 µM; pretreatment for 2 h) significantly inhibits EcSTH-induced phosphorylation of AMPK and ACC1 in HeLa^{Tet-on EcSTH} and MDA-MB-231^{Tet-on EcSTH} cells.
Adv Sci (Weinh)

NADH-Reductive Stress Induced by Dihydrolipoamide Dehydrogenase Activation Contributes to Cuproptosis. [Abstract]

2025 Dec 5:e20444. PMID: 41346305

6-Mercaptopurine purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Dec 5:e20444. [Abstract]

Viability of SH‐SY5Y cells treated with 500 µM CuSO₄ and 100 µM 6-Mercaptopurine (6-MP) , 400 µM AICAR for 24 h (n = 3, unpaired t‐test).
Adv Sci (Weinh)

Targeting Caveolin-1 in Multiple Myeloma Cells Enhances Chemotherapy and Natural Killer Cell-Mediated Immunotherapy. [Abstract]

2025 Jan;12(4):e2408373. PMID: 39630017

6-Mercaptopurine purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jan;12(4):e2408373. [Abstract]

MM1S cells were treated with 6-Mercaptopurine (6-MP, 1.25-10 µM) or daidzin at the indicated concentrations for 48 h and the expression of CAV1 was detected using western blot. The results showed that 6-MP significantly inhibited the expression of CAV1 protein.

6-Mercaptopurine purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jan;12(4):e2408373. [Abstract]

B‐NDG mice were inoculated with MM1S‐Luc cells and randomly divided into six groups (n = 5–7). After 11 days of inoculation, these mice were intraperitoneally injected with 6-Mercaptopurine (6-MP) (10-20 mg/kg), daidzin (30 mg/kg), or vehicle daily until day 67. After 15 days of inoculation, mice were intraperitoneally injected with bortezomib (0.5 mg/kg) three times a week until day 67. The distribution of MM1S‐Luc cells in these mice was measured at the indicated days after inoculation using a living imaging system.

6-Mercaptopurine purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jan;12(4):e2408373. [Abstract]

B‐NDG mice were inoculated with MM1S‐Luc cells and randomly divided into six groups (n = 5–7). After 11 days of inoculation, these mice were intraperitoneally injected with 6‐MP (10-20 mg/kg), daidzin (30 mg/kg), or vehicle daily until day 67. After 15 days of inoculation, mice were intraperitoneally injected with bortezomib (0.5 mg/kg) three times a week until day 67. Kaplan–Meier curve showing mice survival. The results showed that 6-MP further promoted the bortezomib‐mediated survival of MM‐bearing mice.
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 15;6(4):102053. PMID: 40187357
Cell Death Dis

Histidine re-sensitizes pediatric acute lymphoblastic leukemia to 6-mercaptopurine through tetrahydrofolate consumption and SIRT5-mediated desuccinylation. [Abstract]

2024 Mar 14;15(3):216. PMID: 38485947
Pharmacol Res

Identification of Fasudil as a collaborator to promote the anti-tumor effect of lenvatinib in hepatocellular carcinoma by inhibiting GLI2-mediated hedgehog signaling pathway. [Abstract]

2024 Feb:200:107082. PMID: 38280440
ACS Environ Au

Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]

2025 Aug 5;5(6):573-582. PMID: 41277996
Int J Biol Macromol

circE2F1-encoded peptide inhibits circadian machinery essential for nucleotide biosynthesis and tumor progression via repressing SPIB/E2F1 axis. [Abstract]

2024 Sep 15;280(Pt 1):135698. PMID: 39288851
Cell Rep

Structural basis for the reversal of human MRP4-mediated multidrug resistance by lapatinib. [Abstract]

2025 Mar 25;44(4):115466. PMID: 40138312
Anal Chem

Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]

2025 Jun 3;97(21):11099-11109. PMID: 40401576
Life Sci

A protective role of ECSIT in chemotherapy-induced intestinal mucositis by maintaining Lgr5+ intestinal stem cells and gut homeostasis. [Abstract]

2026 Mar 15:389:124236. PMID: 41611204
Int J Pharm

Physicochemical characterization and clinical evaluation of 3D-printed subdivided tablets of 6-Mercaptopurine with broad dosage variations. [Abstract]

2026 Mar 10:692:126648. PMID: 41644072
Commun Biol

Ferroptosis-related gene signature for predicting prognosis and identifying potential therapeutic drug in EGFR wild-type lung adenocarcinoma. [Abstract]

2024 Oct 30;7(1):1416. PMID: 39478024
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Cancers (Basel)

Association between Dysfunction of the Nucleolar Stress Response and Multidrug Resistance in Pediatric Acute Lymphoblastic Leukemia. [Abstract]

2022 Oct 19;14(20):5127. PMID: 36291909
PLoS Negl Trop Dis

Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]

2019 Aug 20;13(8):e0007681. PMID: 31430351
Front Oncol

Hypoxanthine in the microenvironment can enable thiopurine resistance in acute lymphoblastic leukemia. [Abstract]

2024 Jul 19:14:1440650. PMID: 39099696
Res Sq

2026 Jun 15.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 35.71 mg/mL (234.66 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

6.5712 mL

32.8558 mL

65.7117 mL

5 mM

1.3142 mL

6.5712 mL

13.1423 mL

10 mM

0.6571 mL

3.2856 mL

6.5712 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (16.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (16.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (16.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 3.33 mg/mL (21.88 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Kinase Assay^[2]

L6 myotubes are treated with DMSO control or 6-Mercaptopurine hydrate (6-MP) for 24 h, with the final 3 h of incubation including treatments in serum-free DMEM, and further incubated in the absence or presence of 100 nM insulin for 60 min at 37°C. Then, protein lysates (50 μg) are collected and subjected to SDS-PAGE and immunoblotted with primary antibodies against overnight at 4°C. The proteins are finally quantified by densitometric analysis of scanned films using Image J software^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[2]

Cell viability is measured using Cell Viability Assay. L6 skeletal muscle cells are seeded in 96-well plates at a density of 10,000 cells/well and differentiated into myotubes within 7 days. Cells are treated with different doses of 6-Mercaptopurine hydrate (6-MP) for 24 h before the assay. For analysis of cell viability, plates are equilibrated at room temperature for 30 min; 50 μL of Cell Titer-Glo reagent is added to each well, and plates are mixed for 12 min on an orbital shaker. Luminescence is quantified using a luminometer^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration

Around thirteen-week-old pregnant rats are used in this study. The animals are housed individually in wire-mesh cages in an air-conditioned room (temperature, 23±3°C; humidity, 50±20%; ventilation, 10 times/hour; lighting, 12 h light to12 h dark cycle) and are given pelleted diet and water ad libitum. In the experiment, fifteen pregnant rats are injected i.p. with 50 mg/kg 6-Mercaptopurine hydrate (6-MP) on E13, and three dams each are sacrificed by exsanguination from the abdominal aorta under ether anesthesia at 12, 24, 36, 48, and 72 h. Fetuses are collected from each dam by Caesarean section. As controls, fifteen pregnant rats are injected i.p. with 2.0% methylcellulose solution in distilled water at E13, and three dams are sacrificed at each of the same time-points^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Sahasranaman S, et al. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008 Aug;64(8):753-67. [Content Brief]

[2]. Liu Q, et al. 6-Mercaptopurine augments glucose transport activity in skeletal muscle cells in part via a mechanism dependent upon orphan nuclear receptor NR4A3. Am J Physiol Endocrinol Metab. 2013 Nov 1;305(9):E1081-92. [Content Brief]

[3]. Kanemitsu H, et al. 6-Mercaptopurine (6-MP) induces cell cycle arrest and apoptosis of neural progenitor cells in the developing fetal rat brain. Neurotoxicol Teratol. 2009 Mar-Apr;31(2):104-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	6.5712 mL	32.8558 mL	65.7117 mL	164.2792 mL
	5 mM	1.3142 mL	6.5712 mL	13.1423 mL	32.8558 mL
	10 mM	0.6571 mL	3.2856 mL	6.5712 mL	16.4279 mL
	15 mM	0.4381 mL	2.1904 mL	4.3808 mL	10.9519 mL
	20 mM	0.3286 mL	1.6428 mL	3.2856 mL	8.2140 mL
	25 mM	0.2628 mL	1.3142 mL	2.6285 mL	6.5712 mL
	30 mM	0.2190 mL	1.0952 mL	2.1904 mL	5.4760 mL
	40 mM	0.1643 mL	0.8214 mL	1.6428 mL	4.1070 mL
	50 mM	0.1314 mL	0.6571 mL	1.3142 mL	3.2856 mL
	60 mM	0.1095 mL	0.5476 mL	1.0952 mL	2.7380 mL
	80 mM	0.0821 mL	0.4107 mL	0.8214 mL	2.0535 mL
	100 mM	0.0657 mL	0.3286 mL	0.6571 mL	1.6428 mL

Keywords

6-Mercaptopurine

18 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

6-Mercaptopurine

5-Fluorouracil

Cytarabine

Methotrexate

Gemcitabine

6-Thioguanine

Fludarabine

Floxuridine

Clofarabine

Azathioprine

Forodesine

Raltitrexed

Oxaliplatin

Publications Citing Use of MedChemExpress (MCE) 6-Mercaptopurine

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (18)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

6-Mercaptopurine

5-Fluorouracil

Cytarabine

Methotrexate

Gemcitabine

6-Thioguanine

Fludarabine

Floxuridine

Clofarabine

Azathioprine

Forodesine

Raltitrexed

Oxaliplatin

Publications Citing Use of MedChemExpress (MCE) 6-Mercaptopurine

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (18)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

6-Mercaptopurine Related Classifications

HY-13677 Related Classifications